Instrument Inactif

Communiqués Merck & Co., Inc. Euronext Paris

Actions

MRK

US58933Y1055

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

CDC'S ACIP Unanimously Recommends Merck's CAPVAXIVE for Pneumococcal Vaccination in Appropriate Adults	16:07	AQ
EISAI - NEW EFFICACY DATA FOR NON-CLEAR CELL RENAL CELL CARCINOMA FROM KEYNOTE-B61 ADDED TO LENVIMA US LABEL SUPPORTING KEYTRUDA + LENVIMA INDICATION FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RCC	16:06	AQ
Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer	16:06	AQ
Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)	12:54	BU
CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults	02:19	BU
Merck : CDC’s ACIP Unanimously Votes to Add Merck and Sanofi’s Pediatric Hexavalent Combination Vaccine to its Preferential Recommendation to Help Prevent Invasive Hib Disease in American Indian and Alaska Native Infants - Merck.com	27/06	PU
Merck - Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer	27/06	AQ
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer	27/06	BU
USDA Approves Merck Animal Health's NOBIVAC NXT Canine Flu H3N2, The First and Only RNA-Particle Technology Vaccine for Canine Influenza	26/06	AQ
USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza	25/06	BU
Merck - U.S. FDA Approves CAPVAXIVE for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults	18/06	AQ
FDA Approves Merck s KEYTRUDA plus Carboplatin and Paclitaxel as Treatment for Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma	18/06	AQ
U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults	17/06	BU
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma	17/06	BU
Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	05/06	BU
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	04/06	AQ
Anaveon announces IND approval of ANV600-001 Phase I/II clinical study	30/05	AQ
FDA Grants Priority Review to Merck's Application for KEYTRUDA plus Chemotherapy as First-Line Treatment of Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma	30/05	AQ
Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival Endpoint in Patients with High-Risk Early-Stage Triple Negative Breast Cancer	29/05	AQ
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024	29/05	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Merck & Co., Inc. : Une vache à lait qui cache des vedettes

Le 11 juillet 2022 à 11:12